Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Post Chimeric Antigen Receptor T-cEll Therapy fAilUre (PLATEAU Study)

NCT06290622 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT06290622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06290622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Post Chimeric Antigen Receptor T-cEll Therapy fAilUre (PLATEAU Study)
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 1
Overall status
Withdrawn
Start date
August 30, 2024
Completion date
January 31, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, lymphoma, b-cell, lymphoma, follicular